Testing effectiveness (Phase 2)Looking for participantsNCT06412497
What this trial is testing
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Who this might be right for
Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota 60